NovaBay Pharmaceuticals
Biopharmaceutical company
From Wikipedia, the free encyclopedia
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.[1] and NeutroPhase, used in treatment of Necrotizing Fasciitis[2][3]
 | |
| Type | Public |
|---|---|
| AMEX: NBY Russell Microcap Index component | |
| Founded | 2000 |
| Founder | Ron Najafi |
| Headquarters | United States  |
| Key people | Mark Sieczkarek, M.B.A., CEO and Chairman of BOD John (“Jack”) McGovern, CFO Tom Paulson, M.B.A., Strategic Planning Lewis J. Stuart, M.B.A., Chief Commercial Officer (CCO) Glenn Moro, VP, Marketing Avenova Justin M. Hall, Esq, Senior Vice President, General Counsel Greg Miller, Director, Strategic Sales |
| Website | novabay |
History
NovaBay Pharmaceuticals, Inc. was founded in 2000 by Ron Najafi to create a stable version of HOCl.[4][citation needed] Najafi, chemistry Nobel laureate Herbert C. Brown, and Purdue University Professor Dale Margerum recruited Dr. Lu Wang to become NovaBay's Director of Product Development.[citation needed] She developed the stable version of pure hypochlorous acid, without bleach impurities, which became NovaBay's first product, NeutroPhase.[5][6][7][8]
NovaBay later launched additional products named CelleRx™ for Plastic Surgery and i-Lid™ Cleanser (Now Avenova) that was cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.[9]
